Summit Therapeutics stock is trading -10.59% below its average target price of $10.67 after dropping -4.7% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $5.0 to $14.0 per share.
Summit Therapeutics has an elevated short interest of 22.4%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.81. Since 88.14% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Summit Therapeutics's rate of institutional ownership stands at 7.3%, which is lower than average and further confirms the lack of market confidence in the stock. As a result, Market Inference considers Summit Therapeutics to be the subject of mixed market sentiment.
Institutions Invested in Summit Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Blackrock Inc. | 1% | 9,823,341 | $93,714,672 |
| 2024-03-31 | State Street Corporation | 1% | 8,114,230 | $77,409,753 |
| 2024-03-31 | FMR, LLC | 1% | 7,974,531 | $76,077,025 |
| 2024-03-31 | Vanguard Group Inc | 1% | 7,269,243 | $69,348,577 |
| 2024-03-31 | Geode Capital Management, LLC | 0% | 3,152,390 | $30,073,800 |
| 2024-03-31 | Northern Trust Corporation | 0% | 1,072,714 | $10,233,691 |
| 2024-03-31 | Charles Schwab Investment Management, Inc. | 0% | 1,016,545 | $9,697,839 |
| 2024-03-31 | Morgan Stanley | 0% | 692,541 | $6,606,841 |
| 2024-03-31 | Goldman Sachs Group Inc | 0% | 680,601 | $6,492,933 |
| 2024-03-31 | Rafferty Asset Management, LLC | 0% | 650,286 | $6,203,728 |
